CHITTARANJAN ANDRADE, MD., Additional Professor & Head, Department of Psychopharmacology, NIMHANS, Bangalore-560 029.
Indian J Psychiatry. 2000 Jul;42(3):308-11.
Lorazepam is commonly prescribed to treat insomnia in depressed patients who receive electroconvulsive therapy (ECT); however, lorazepam may interfere with ECT seizure parameters, and may thereby compromise the efficacy of the treatment. This study therefore sought to assess whether zopicione, a hypnotic agent, interferes less with the ECT seizure. For ethical reasons, the study utilized an animal model. Sprague-Dawley rats (n=10/group) received either zopicione (1.5 mg/ kg), lorazepam (0.2 mg/kg), or a placebo equivalent. After 30 minutes, an electroconvulsive shock was administered to the rats. It was observed that the motor seizure duration but not the total motoric phase was significantly attenuated by zopicione. Lorazepam did not impact significantly upon either seizure measure. It is concluded that zopicione may be a suitable hypnotic for patients receiving ECT only if sufficient time is allowed for the drug to be substantially washed out of the body.
劳拉西泮常用于治疗接受电休克治疗（ECT）的抑郁患者的失眠症；然而，劳拉西泮可能会干扰 ECT 发作参数，从而影响治疗效果。因此，这项研究旨在评估催眠剂佐匹克隆是否对 ECT 发作的干扰较小。出于伦理原因，该研究使用了动物模型。斯普拉格-道利大鼠（每组 10 只）分别给予佐匹克隆（1.5mg/kg）、劳拉西泮（0.2mg/kg）或等量安慰剂。30 分钟后，对大鼠进行电休克。观察到佐匹克隆显著缩短了运动性发作持续时间，但对总运动相没有显著影响。劳拉西泮对两种发作指标均无显著影响。结论是，如果有足够的时间使药物从体内大量清除，佐匹克隆可能是接受 ECT 的患者合适的催眠药物。
